Perivision raises CHF 1.1 Million

PeriVision, Inselspital and the University of Bern receive a CHF 1.1 Million grant to build new functional eye tests in retinal diseases like age-related macular degeneration (AMD), geographic atrophy (GA) or diabetic retinopathy (DR) which affect hundreds of millions worldwide.

Normally, patients with AMD, GA or DR struggle with standard eye tests such as visual acuity or microperimetry, because they cannot fixate their gaze on a stimulus easily. Yet, functional understanding is crucial in treatment decisions and demonstrating quality-of-life improvements. Therefore, we will build fixation-independent eye tests for these patients leveraging PeriVision’s AI, VR & software engineering capabilities.

Prof. Dr. Raphael Sznitman, a co-founder at PeriVision and professor for AI in Medicine at the University of Bern, commented on the joint research project: “We are very happy to build this expansion of functional eye tests into retinal diseases on the successful research project in visual field-testing for glaucoma. Our teams have been working side-by-side for many years, and this long-standing relationship between the largest eye clinic in Switzerland and the research institute is a very fertile ground for novel technical solutions to actual clinical problems.”

Clinical trial agreement signed with Roche / Genentech 

Perivision also announced having signed an agreement with Genentech, the US business unit of Roche, to evaluate the potential use of the VisionOne platform in ophthalmology clinical trials over the next few months. The starup is eager to showcase its capabilities in improving clinical research to ultimately advance the development and market access of new treatments for eye diseases.

➡️ Source: Press Release.

📸 Perivision